IDXX IDEXX LABORATORIES INC /DE Insider Trading

EVP Hunt Nimrata sold 1,758 IDXX shares at $634.57 (now $618.92); 4 of 4 prior same-ticker sales showed 90d declines.

Hunt Nimrata sold 1,758 shares of IDEXX on 2026-03-03 at $634.57, reducing her holdings by 8.8% to 18,140 shares. The stock has since declined to $618.92 (−19.3% from the 52-week high). Notably, her prior same-ticker trade history shows a strong timing pattern: all 4 measurable prior sales at IDXX were well-timed at the 90-day mark, with negative returns ranging from −8.4% to −8.8% after the sale dates. The current transaction aligns with this historical pattern—the stock has already moved −2.2% in the 30 days following the sale. IDEXX trades at a P/E of 41.10 with recent quarterly net income of $274,610,000.00, so investors should monitor whether this latest sale precedes further weakness consistent with her past execution.

CEO Mazelsky sells 23,326 shares of IDXX for $15.3M across 13 transactions on 2026-02-26; stock down 5.0% (30d), 13.1% (90d), trading 17.0% below 52-week high

Jonathan Jay Mazelsky, President and CEO of IDEXX Laboratories, executed 13 separate sales totaling 23,326 shares for $15,338,080.79 at prices ranging from $650.67 to $662.16. This represents a -21.8% reduction in his post-transaction holdings to 83,803 shares. The transaction occurred as IDXX traded at $657.55 (blended average price) while currently trading at $636.70, and the stock has declined 5.0% over the preceding 30 days and 13.1% over the preceding 90 days. His prior five IDXX sales (all on 2025-08-06) yielded positive 90-day returns of +12.9%, +14.9%, +14.6%, +14.5%, and +14.3%, indicating those sales were poorly timed relative to subsequent price appreciation. The current filing's timing relative to forward returns cannot yet be assessed, but investors should note the substantial scale of this position reduction and the recent price deterioration in the name.

EVP Hunt Nimrata sold 2,693 IDXX shares at $661.54; 4 of 5 prior IDXX sales were well-timed.

Hunt Nimrata sold 2,693 shares (11.9% of pre-transaction holdings) at $661.54, leaving her with 19,898 shares at IDEXX LABORATORIES INC. Against her same-ticker history at IDXX, this sale extends a pattern of well-timed selling: 4 of 5 prior trades at this ticker captured declines, with 90-day returns of -8.8%, -8.4%, -8.6%, and -8.7% following those sales. The stock is now trading at $656.73, down -14.3% from its 52-week high of $766.68, suggesting the recent price pressure aligns with her historical timing edge at this specific ticker. Her broader cross-ticker track record shows a 50% well-timed rate on sells with average 90-day returns of +2.1%, but her IDXX-specific execution has been notably sharper—4 of 5 prior same-ticker sales preceded material declines rather than gains. The company remains fundamentally solid with $1.1B in quarterly revenue and 10.4% annual growth, but the cumulative selling pattern and recent 90-day decline of -12.8% merit observation.

EVP Michael G Erickson sold 5,371 shares for $3.4M at blended avg $627.38 on 2026-02-17

Michael G Erickson, EVP at IDEXX, executed 6 separate sales totaling 5,371 shares for $3,369,666.17 on 2026-02-17. The disposition reduced his holdings by 26.2%, from 20,463 to 15,092 shares. The stock has declined 17.7% from its 52-week high of $766.68 and 8.1% over the prior 30 days, suggesting the sales occurred amid recent downward momentum. Without information on trading plan status or prior track record context, the transaction represents a material reduction in executive holdings at a point of price weakness relative to recent peaks.

IDXX EVP Fennell George sells 11,345 shares for $7.3M across 8 transactions, reducing holdings by -53.6%.

George executed 8 separate sales on 2026-02-10 totaling 11,345 shares (11.3K shares) for $7,336,993.27 ($7.3M) at an average price of $646.72, reducing his holdings from 21,168 shares to 9,823 shares (a -53.6% reduction). This substantial liquidation comes as IDXX trades 15.4% below its 52-week high, with the stock down 10.5% over the prior 30 days and 7.5% over 90 days. Reviewing his same-ticker history at IDXX, George's prior 5 sales showed a 80% well-timed rate at the 90-day mark (4 of 5 preceded subsequent declines), with the most recent sale on 2025-02-10 followed by -10.8% over 30 days. His cross-ticker track record documents a 83.33% well-timed rate on 6 prior sells with average 90-day returns of -11.6%, suggesting a pattern of selling ahead of downward moves. The magnitude of this reduction—eliminating more than half his position in a single filing—paired with his demonstrated prior timing accuracy and current negative price momentum, deserves investor attention as a data point in assessing near-term stock direction.

EVP Hunt Nimrata sells 9,425 shares (30.8% reduction) for $6,629,013.52 at IDXX on 2025-11-07

Hunt Nimrata, Executive Vice President, executed 4 separate sales totaling 9,425 shares for $6,629,013.52 on 2025-11-07, reducing her holdings from 30,573 to 21,148 shares (a 30.8% reduction). The blended average price of $703.34 is near the 52-week high of $722.94 (approximately 2.7% below peak), executed during a strong uptrend where the stock has advanced 15.2% in 30 days and 8.8% in 90 days. Her prior same-ticker sales at IDXX in August 2025 showed mixed timing outcomes, with 0 of 4 prior sells proving well-timed at the 90-day mark; August sales subsequently posted positive returns of +7.9% to +14.6%, suggesting she sold before stock appreciation. The current holding of 21,148 shares demonstrates substantial ongoing ownership, which constrains any inference of fundamental concern while still representing a material reduction in her concentrated position.

Director SZOSTAK M ANNE sold 2,187 shares (89.4% of holdings) at $647.33, leaving only 259 shares; stock now -6.0% from 52-week high.

Director SZOSTAK M ANNE executed a substantial reduction in her IDXX stake, selling 2,187 shares at $647.33 and retaining just 259 shares post-transaction, representing a -89.4% net change in her open position. The sale occurred near the stock's 52-week high—the transaction price of $647.33 is within 0.8% of the 52-week peak of $682.78, and the stock currently trades at $641.72, -6.0% from that high. Her prior three sales at IDXX yielded positive 90-day returns (+2.0%, +2.3%, +5.2%), indicating those previous exits were poorly timed (stock subsequently rose); this pattern suggests prior sales did not precede material declines. The timing context here—selling near a 52-week high after the stock gained +13.5% over 30 days and +24.8% over 90 days—differs from her recent pattern of selling before subsequent appreciation, though the forward outcome remains unknown.

EVP Hunt Nimrata sold 1,200 shares of IDXX at $656.53 on 2025-08-11, reducing holdings by 6.2% to 18,032 shares.

Hunt Nimrata, EVP, sold 1,200 shares for $787,840.20, reducing her holdings from 19,232 to 18,032 shares. This sale occurred as the stock was up 24.9% over 30 days and 29.7% over 90 days, trading at $663.92 currently versus a 52-week high of $682.78. The company's fundamentals show stable quarterly revenue of $1,109,457,000 with net income of $293,989,000, though the elevated P/E of 53.89 reflects market expectations. Notably, the insider executed three separate sales on 2025-08-06 (outcomes not yet measurable), followed by this transaction five days later, suggesting a structured approach to position reduction rather than a reactive market timing decision.

EVP/GC Underberg sold 5,450 IDXX shares for $3.6M at $651.60, reducing holdings by 46.2% amid 90-day +28.0% rally.

Underberg sold 5,450 shares at $651.60, realizing $3,551,220.00 in proceeds and reducing her holdings from 11,788 to 6,338 shares. The transaction occurred as IDXX has appreciated 28.0% over the prior 90 days and stands 22.3% higher on a 30-day basis, placing the stock 4.5% below its 52-week high. The 46.2% reduction in her post-transaction holdings represents a substantial portfolio reduction, not a routine trim. With IDXX trading at a P/E of 52.94 and the company reporting annual revenue growth of +6.5%, the sale warrants review of the sell-side rationale—specifically whether this reflects a reassessment of valuation given recent momentum, or other portfolio or tax-planning factors.

EVP Lane Michael sold 8,411 shares at $627.56–$628.89 for $5.3M; position cut 54.1%, leaving 7,131 shares held.

Lane Michael, Executive Vice President of IDEXX LABORATORIES, executed 3 separate sales totaling 8,411 shares for $5,279,893.42 on 2025-08-06, reducing his holdings by 54.1% from 15,542 to 7,131 shares. The blended average sale price of $627.74 sits below the current price of $658.06, and the 30-day change shows +21.7% upward momentum. Notably, his prior sell at this same ticker (2023-08-03) was well-timed at the 90-day mark, with the stock declining -22.5% after the sale. This current substantial reduction in shareholding—eliminating more than half his position—occurs in a market environment where IDXX has risen strongly in recent months (+33.8% over 90 days), and at a valuation of 53.41 P/E. The scale and timing of this liquidation relative to his prior sell pattern merit investor attention as a data point in assessing sentiment among senior management.